Clinical differences between men and women with psoriatic arthritis: Relevance of the analysis of genes and polymorphisms in the major histocompatibility complex region and of the age at onset of psoriasis by Queiro Silva, Rubén et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2013, Article ID 482691, 7 pages
http://dx.doi.org/10.1155/2013/482691
Clinical Study
Clinical Differences between Men and Women with Psoriatic
Arthritis: Relevance of the Analysis of Genes and Polymorphisms
in the Major Histocompatibility Complex Region and of the Age
at Onset of Psoriasis
Rubén Queiro,1,2 Patricia Tejón,1 Pablo Coto,2,3 Sara Alonso,1
Mercedes Alperi,1 Cristina Sarasqueta,4 Segundo González,5 Jesús Martínez-Borra,6
Carlos López-Larrea,6 and Javier Ballina1
1 Rheumatology Department, Hospital Universitario Central de Asturias (HUCA), C/Celestino Villamil s/n,
Oviedo, 33006 Asturias, Spain
2 Psoriasis Unit, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, Spain
3 Dermatology Department, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, Spain
4Clinical Epidemiology Unit, BIODONOSTIA, San Sebastian, Basque Country, Spain
5 Department of Functional Biology, Oviedo University School of Medicine, Oviedo, Asturias, Spain
6 Immunology Service, HUCA, Oviedo, Asturias, Spain
Correspondence should be addressed to Rube´n Queiro; rubenque7@yahoo.es
Received 16 September 2012; Revised 17 March 2013; Accepted 28 March 2013
Academic Editor: Chung Tei Chou
Copyright © 2013 Rube´n Queiro et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
It has been shown that males with spondyloarthritis tend to suffer frommore severe spinal disease while females are more likely to
have peripheral joint involvement. Nevertheless, gender-related differences have not been thoroughly explored in psoriatic arthritis
(PsA). In PsA, males accumulate more peripheral and axial joint damage compared to women. However, it is not clear whether
these findings are secondary to differences in occupational physical activity, hormonal changes, or other factors. The present study
analyzed the differences in clinical expression of PsA between men and women. We have also evaluated the possible existence
of gender-linked differences in the distribution of genes and polymorphisms within the major histocompatibility complex and
whether patients’ age at the onset of psoriasis established any differences in these aspects. Women suffered more polyarthritis,
greater functional impairment, and a larger number of swollen joints during followup. We appreciated a differential expression of
certain MHC genes according to gender and age at onset of psoriasis. Our results point to the need to include patient’s age at the
onset of psoriasis and gender as key stratification elements in future studies of genetic associations in PsA.
1. Introduction
Psoriasis is a relatively common T-cell mediated cutaneous
disease in which both environmental and genetic factors
contribute to its pathogenesis [1]. Despite multiple suscepti-
bility loci for psoriasis that have been identified, the PSORS1
locus located in the MHC class I region on chromosome
6p21.3 confers the most risk for psoriasis [1]. However, the
extensive ranges of polymorphism and the preservation of
HLA haplotypes in most populations have made it diffi-
cult to characterize the exact gene responsible for psoriasis
susceptibility located in PSORS1. Nevertheless, HLA-C∗06
is the strongest association found in psoriasis and is the
only genetic variant repeatedly observed to be associated
with psoriasis in most of the populations (1). Additionally,
other MHC genes have also been associated with psoriasis
independently of HLA-C∗06 [2, 3].
Psoriatic arthritis (PsA) is a chronic inflammatory joint
disease which affects a significant proportion (10–40%) of
psoriatic patients [4, 5]. HLA-C∗06 has also been associ-
ated with PsA susceptibility (6). MICA-A9 (corresponding
to MICA∗002) polymorphism has been further associated
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with arthritis susceptibility but not with psoriasis [6–8].
Additionally, HLA-B38, HLA-B39, HLA-B57, HLA-DR7, and
TNF-𝛼 promoter polymorphisms have been associated with
PsA susceptibility in the past; however, these alleles are
in linkage disequilibrium (LD) with HLA-C∗06 or MICA-
A9 [6–8]. Thus, it has been postulated that there are two
different susceptibility loci associated with PsA in the MHC
region: HLA-C∗06, which is associated with the skin lesions
(present in the extended haplotypes-EH-13.1, 37.1, and 57.1)
and another, MICA-A9, associated with susceptibility to
arthritis and present in EH38.1, EH39.1, and EH57.1. There-
fore, haplotype EH57.1 (HLA-C∗06-B57-DRB1∗07-DQA1∗02-
DQB1∗03) is associatedwith both psoriasis and inflammatory
arthropathy.
It has been shown that males with spondyloarthritis tend
to suffer from more severe spinal disease while females are
more likely to have peripheral joint involvement [9]. Never-
theless, gender-related differences have not been thoroughly
explored in PsA. In a recent investigation among patients
with PsA, men tended to accumulate more peripheral and
axial joint damage compared to women. However, it was
unclear whether these findings were secondary to differences
in occupational physical activity, hormonal changes, or other
factors [10]. It is also plausible that some of these gender-
observed differences in PsA could be attributed to genetic
factors. Indeed, some studies have shown a close correlation
between male sex, HLA-B27 positivity, and risk of psoriatic
spondyloarthritis [11, 12]. Very few studies have investigated
whether there are differences in the clinical and genetic risk
profiles between men and women with PsA [13].
The present study analyzes the differences in clinical
expression of PsA between men and women. We have also
evaluated the possible existence of gender-linked differences
in the distribution of genes and polymorphisms within the
MHC and whether patients’ age at the onset of psoriasis
establishes any differences in these aspects.
2. Patients and Methods
2.1. Patients. One-hundred ten consecutive patients who
fulfilled theClassification criteria for psoriatic arthritis (CAS-
PAR) criteria [14] were randomly selected from the rheuma-
tology outpatient clinic of a tertiary care hospital. There were
55 men and 55 women with a mean age of 48 ± 12 years. The
mean disease duration for psoriasis was 19 ± 10 years and
13 ± 8 years for arthritis. Psoriasis preceded the arthritis in
75% of cases and a family history of psoriasis was recorded
in 43% of patients. The joint patterns on the baseline visits
were those described by Moll and Wright [15], though in the
final analysis increased emphasis was placed on the dominant
joint pattern over the last 5 years of followup. Accordingly,
39% had oligoarthritis, 29% polyarthritis, and 32% presented
a predominantly axial disease. Distal interphalangeal joint
disease was seen in 32% of patients, whereas nail disease
was seen in 43.6%. Dactylitis was noted in 30% of patients.
Clinical enthesitis was present in 30% of subjects. All the dis-
ease variables, including laboratory, clinical and exploratory
tests, disease activity, physical function, joint counts, and
radiological studies were investigated on a standard basis in
both men and women. The population was stratified by age
at the time of onset of psoriasis, adopting a cutoff point of
40 years for distinguishing between early and late psoriasis.
The study was carried out with the approval of the ethics
committee of our hospital. All patients gave written informed
consent before enrolling in the study.
2.2. HLA Typing. Human leukocyte antigen, HLA-C, was
typed using the polymerase chain reaction with sequence-
specific primers (PCR-SSP) [7]. The polymorphisms of
the octamer transcription factor 3 gene (OTF3), the cor-
neodesmosin gene (CDSN), and the a-helix coiled-coil rod
homologue (HCR) gene were analyzed as described pre-
viously [7]. The microsatellites C1 2 5 and C1 4 4 were
amplified using the PCR primers described by Tamiya et al.
[16]. HLA-B typing was carried out using the Dynal RELI
SSO HLA-B test following the manufacturer’s instructions.
HLA-DRB1 alleles were typed and subtyped by performing
polymerase chain reaction using specific primers (PCR-SSP).
For the analysis of microsatellite repeat polymorphism in the
MICA gene, PCR was carried out using primers labeled at
the 5󸀠 end with the fluorescent reagent Cy5 as previously
described [7]. ForMICB typing, a dinucleotide microsatellite
polymorphism in the first intron was analyzed by PCR
analysis and TNF-𝛼 polymorphism at positions −238 and
−308 was typed by PCR as previously described [7]. The
distribution of these markers was analyzed in the whole
group as well as in both men and women separately. This
distribution was also analyzed according to patients’ age at
the onset of psoriasis, using the previously mentioned cutoff
point. All previous typing was also performed in a control
population of 110 (55 men and 55 women) random blood
donors matched ethnically and geographically.
2.3. Statistical Analysis. Thedifferences between the frequen-
cies of these allelic markers in patients and controls, as well
as the differences found in accordance with sex and age at
disease onset, were assessed by univariate analysis using a
Fisher’s exact test, chi-squared test with Yates’ correction
and a Student’s t-test. The differences between genders
corresponding to the categorical variables were assessed with
Fisher’s exact test, while Student’s t-test was used in the
case of the continuous variables. The odds ratio (OR) was
calculated by the cross-product ratio and the 95% confidence
intervals by the cornfield method. The P significant values
were corrected (𝑃
𝑐
) by multiplying them by the number of
alleles at each locus. The extent of linkage disequilibrium
between two loci is expressed as the observed disequilibrium
value (𝜆s), that is, a proportion of the theoretical maximum
disequilibrium value (𝜆max) achievable for this combination
of alleles. The 𝜆s were calculated using the formula: 𝜆s =
𝜆/𝜆max = Pab − (Pa ⋅ Pb)/Pa ⋅ (1 − Pb).
3. Result
3.1. Differences in the Clinical Variables of Disease between
Men and Women. Compared to PsA males, females tended
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Table 1: Clinical characteristics of the study population.
Variables Men Women 𝑃valuesn: 55 n: 55
Age (yr) 46.5 ± 11.6 46.4 ± 15.9 NS
Psoriasis onset age (yr) 27.5 ± 10.4 27.0 ± 14.9 NS
Arthritis onset age (yr) 34.2 ± 9.4 35.1 ± 13.1 NS
Psoriasis duration (yr) 19 ± 11 18.2 ± 8.8 NS
Arthritis duration (yr) 13 ± 7.4 12.5 ± 6.7 NS
Psoriasis-arthritis latency (yr) 7 ± 6.4 7.5 ± 5.6 NS
Family history 40% 45.5% NS
Oligoarthritis 42% 34.5% NS
Polyarthritis 20% 40% <0.05
Axial disease 38.2% 23.6% NS
Nail disease 36.4% 47.3% NS
DIP disease 29% 34.5% NS
IBP (ever) 62% 67.3% NS
Enthesitis 34.5% 25.5% NS
Dactylitis 31% 31% NS
HAQ 0.62 ± 0.42 1.10 ± 0.53 <0.01
Swelling joint count 3.4 ± 4.2 5.2 ± 4.6 <0.05
Tender joint count 10.2 ± 3.4 11.0 ± 4.1 NS
Erosive disease 34.5% 41.8% NS
PASI 5.4 ± 4.5 5.7 ± 3.8 NS
VSG 15 ± 5.3 16 ± 4.7 NS
HLA-C∗06 56.4% 56.4% NS
HLA-B27 36.4% 27.3% NS
DIP: distal interphalangeal joint. IBP: inflammatory back pain. HAQ: Health
Assessment Questionnaire. PASI: Psoriasis Area and Severity Index.
to be affected more frequently by polyarthritis as the main
joint pattern during followup (40% versus 20%, 𝑃 < 0.05),
higher HAQ values (1.10 ± 0.53 versus 0.62 ± 0.42, 𝑃 <
0.01), and higher swelling joint count (5.2 ± 4.6 versus 3.2
± 4.2 𝑃 < 0.05). There were no gender differences in age at
the onset of psoriasis or arthritis, family history of disease,
distal interphalangeal involvement, dactylitis, nail disease,
the presence of erosive disease in the radiological study, or
severity of psoriasis (Table 1).
3.2. Differences in Disease Variables betweenMen andWomen
according to Age at the Onset of Psoriasis (Cutoff Point 40
Years). Most patients developed psoriasis before 40 years of
age (45 men and 40 women). These individuals showed a
family history of psoriasis in 47 cases (40%), while the rest of
the patients with psoriasis first manifesting after 40 years of
age presented antecedents of the disease in only three cases
(12%), 𝑃 < 0.05. In general, the psoriasis-arthritis latency
period was significantly shorter in patients with late psoriasis
(3.5 ± 3.4 years) than in subjects with early psoriasis (7.3±5.4
years) (𝑃 < 0.01). The only discordant data between genders
in the patients with psoriasis developing before 40 years of
age were a shorter psoriasis-arthritis latency period in men
(5.5 ± 7.1 years) than in women (9.3 ± 6.6 years) (𝑃 < 0.01),
and a greater frequency of polyarthritis during followup in
women (37.5% versus 17.7%) (𝑃 < 0.05). Women with early
psoriasis showed greater nail involvement than men, though
the difference was not statistically significant. In women with
type II psoriasis, polyarthritis likewise was the dominant PsA
pattern (53.3% versus 30%), though the differences failed to
reach statistical significance, due to the small number of cases
in this group. In the same way, in men with type II psoriasis,
the dominant joint patternwas axial involvement (70% versus
33.3%), though once again the differences failed to reach
statistical significance, due to the small number of cases in
this group (Table 2).
3.3. Comparative Distribution of MHC Genetic Markers
between Men and Women. The global study population
showed a relationship between the presence of HLA-C∗06
(56.4% versus 17%, OR 6.18, 95% CI: 3.32–11.5, 𝑃
𝑐
< 0.0001),
MICA-A9 (60% versus 30%, OR 3.5, 95% CI: 2.0–6.12, 𝑃
𝑐
<
0.001), and HLA-B∗27 (31.8% versus 7.3%. OR 5.9, 95% CI:
2.6–13.4, 𝑃
𝑐
= 0.001) and the risk of suffering PsA. Subjects
expressing HLA-C∗06 were significantly younger at the time
of onset of psoriasis (24 ± 13.6 years) than the individuals
without this allele (32.4 ± 14.1 years), 𝑃 = 0.01. With
respect toHLA-C∗06 and family history, 64% of subjects who
showed a positive family history had this allele compared to
44% of those with no family history, OR 2.3, 95% CI: 0.82–
6.36, 𝑃 = 0.08. MICA-A9 showed no association with a
family history of psoriasis or with patient’s age at onset of the
disease. However, the patients with allele 384 of the C1 4 4
microsatellite, telomeric to HLA-C, were significantly older
at the onset of psoriasis (35.3 ± 12.6 versus 25.1 ± 13.7 years,
𝑃 = 0.01) and of arthritis (42 ± 11.5 versus 33 ± 11.7 years,
𝑃 = 0.01). In the same way as MICA-A9, this microsatellite
was not associated with a family history of disease.
The following markers were overexpressed in women
with PsA: HLA-B∗27 (27.3% versus 7.3%. OR 4.8, 95% CI:
1.5–15.5, 𝑃
𝑐
= 0.01), HLA-C∗06 (56.4% versus 16.4%. OR 6.6,
95% CI: 2.7–16.1, 𝑃
𝑐
= 0.0001), C∗07 (49% versus 25.5%. OR
2.8, 95% CI: 1.3–6.3, 𝑃
𝑐
= 0.01), TNF-308A (45.5% versus
22%. OR 3.0, 95% CI: 1.3–6.9, 𝑃
𝑐
= 0.009), and MICA-A9
(60% versus 32.7%. OR 3.1, 95% CI: 1.4–6.7, 𝑃
𝑐
= 0.004). In
turn, in men only the following markers were significantly
elevated with respect to the male control population: HLA-
C∗06 (56.4% versus 18.2%. OR 5.8, 95% CI: 2.4–13.8, 𝑃
𝑐
=
0.0001), HLA-B∗27 (36.4% versus 7.3%. OR 7.3, 95% CI: 2.3–
23.2, 𝑃
𝑐
= 0.0004), and MICA-A9 (60% versus 27.3%. OR 4.0,
95% CI: 1.8–8.9, 𝑃
𝑐
= 0.001).
In reference to the relationship between the genes regulat-
ing disease risk and the differential clinical features, 17 out of
24 women with nail disease were C∗06 positive (71%) versus
only 6 out of 20 males with nail disease (30%), 𝑃 < 0.01. The
psoriasis-arthritis latency period was significantly shorter in
MICA-A9 positive men (5.4 ± 6.6 years) than in women with
thismarker (8.2±6.4 years),𝑃 < 0.01. Similarly, the psoriasis-
arthritis latency period was significantly shorter in men with
the 384 allele of C4 1 1 (5.1 ± 6.1 years) than in women with
this same microsatellite (8.1 ± 6.1 years), 𝑃 < 0.01.
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Table 2: Differences between men and women according to age at
psoriasis onset (cutoff: 40 years).
(a) Age at psoriasis onset <40
Variable Men Women 𝑃valuesn: 45 n: 40
Age (yr) 46.3 ± 8.5 48.6 ± 14.6 NS
Arthritis onset age (yr) 35.5 ± 6.8 37.6 ± 10.6 NS
Psoriasis onset age (yr) 25 ± 8.2 22 ± 9.9 NS
Psoriasis duration (yr) 16.3 ± 14.1 21 ± 9.2 0.07
Arthritis duration (yr) 10.9 ± 9.5 11 ± 8.9 NS
Psoriasis-arthritis latency (yr) 5.5 ± 7.1 9.3 ± 6.6 <0.01
Family history 44.4% 50% NS
Oligoarthritis 46.7% 40% NS
Polyarthritis 17.7% 37.5% <0.05
Axial disease 33.3% 22.5% NS
DIP disease 26.7% 40% NS
Nail disease 37.8% 52.5% NS
Enthesitis 35.6% 27.5% NS
Dactylitis 25.5% 35% NS
Erosive disease 33.3% 40% NS
HAQ 0.7 ± 4.5 0.8 ± 6.2 NS
SJC 3.3 ± 4.6 4.3 ± 3.2 NS
TJC 8.2 ± .5.2 9.2 ± 5.5 NS
PASI 7.3 ± 3.4 8.1 ± 4.4 NS
(b) Age at psoriasis onset >40
Variable Men Women 𝑃valuesn: 10 n: 15
Age (yr) 59.4 ± 8.4 67.1 ± 8.2 0.03
Arthritis onset age (yr) 49.4 ± 3.4 52.5 ± 9.6 NS
Psoriasis onset age (yr) 45.7 ± 3.4 51.2 ± 6.9 <0.05
Psoriasis duration (yr) 13.6 ± 8 15.9 ± 5.3 NS
Arthritis duration (yr) 9.9 ± 5.9 14.5 ± 9 NS
Psoriasis-arthritis latency (yr) 3.7 ± 3.3 3.2 ± 3.6 NS
Family history 10% 13.3% NS
Oligoarthritis 0% 20% NS
Polyarthritis 30% 53.3% NS
Axial disease 70% 33.3% NS
DIP disease 30% 13.3% NS
Nail disease 30% 20% NS
Enthesitis 30% 20% NS
Dactylitis 30% 20% NS
Erosive disease 40% 46.7% NS
HAQ 0.8 ± 5.1 0.9 ± 5.3 NS
SJC 3.2 ± 4.6 4.7 ± 4.4 NS
TJC 10.3 ± 4.1 11.3 ± 5.2 NS
PASI 4.2 ± 2.3 3.8 ± 3.6 NS
DIP: distal interphalangeal joint. HAQ: Health Assessment Question-
naire. SJC: swelling joint count. TJC: tender joint count. PASI: Psoriasis
Area and Severity Index.
3.4. Distribution of Genetic Markers according to Patient Age
at Onset of Psoriasis. There were no significant differences
in age at the onset of psoriasis between men and women
with early psoriasis and HLA-C∗06 positivity (21±8.3 versus
18.1 ± 8.9 years, resp.). However, among the individuals with
late psoriasis (over 40 years of age) and HLA-C∗06 positivity,
the age at onset of psoriasis was significantly younger in men
(44.3 ± 3.2 years) than in women (57 ± 4.2 years), 𝑃 < 0.01.
Similarly, men with C1 4 4 (384) microsatellite positivity
and the development of psoriasis after 40 years of age were
significantly younger at disease onset (45.7 ± 3.8 years) than
the women with the same marker (53.3 ± 7 years), 𝑃 < 0.01.
The women developing psoriasis before 40 years of age (n
= 40) showed significant elevation of the following markers
versus the female control population: HLA-C∗06 (65% versus
16.4%. OR 9.5, 95% CI: 3.6–24.9, 𝑃
𝑐
= 0.0001), HLA-C∗07
(50% versus 25.5%. OR 2.9, 95% CI: 1.2–6.9, 𝑃
𝑐
= 0.02), HLA-
∗B27 (30% versus 7.3%. OR 5.5, 95% CI: 1.6–18.5, 𝑃
𝑐
= 0.005),
and MICA-A9 (62.5% versus 32.7%. OR 3.4, 95% CI: 1.5–8.0,
𝑃
𝑐
= 0.006).The women developing psoriasis after 40 years of
age (𝑛 = 15) in turn showed over-expression of the following
markers: TNF-308A (66.7% versus 22%. OR 9.0, 95%CI: 2.6–
31.2, 𝑃
𝑐
= 0.004) and HLA-DR17–DRB1∗03- (53% versus 18%.
OR 5.1, 95% CI: 1.5–12.5, 𝑃
𝑐
= 0.01).
The men developing psoriasis before 40 years of age (𝑛 =
45) showed over-expression of the following markers: HLA-
C∗06 (58% versus 18.2%. OR 6.2, 95% CI: 2.5–15.2, 𝑃
𝑐
=
0.0001), B∗27 (42.2% versus 7.3%. OR 9.3, 95% CI: 2.9–30.2,
𝑃
𝑐
= 0.001), and MICA-A9 (60% versus 27.3%. OR 4.0, 95%
CI: 1.7–9.3, 𝑃
𝑐
= 0.001).Themen developing psoriasis after 40
years of age (𝑛 = 10) in turn showed a significant increase in
the followingmarkers: HLA-C∗06 (50% versus 18.2%.OR 4.5,
95% CI: 1.1–18.5, 𝑃
𝑐
= 0.04), MICB-CA23 (50% versus 5.5%.
OR 17.3, 95% CI: 3.2–94.9, 𝑃
𝑐
= 0.001), C1 4 4 (80% versus
22%. OR 14.3, 95% CI: 2.7–76.7, 𝑃
𝑐
= 0.0007), and MICA-A9
(60%versus 27.3%.OR4.0, 95%CI: 1.0–16.2,𝑃
𝑐
=0.05) (Tables
3 and 4).
4. Discussion
Spondyloarthritic disorders are generally diagnosed more
often inmen than inwomen [17]. In reference to themost rep-
resentative form of these disorders, ankylosing spondylitis,
three male cases are documented for every female case [17].
However, since the introduction of the new ASAS criteria
for axial spondyloarthritis, these differences are no longer
so apparent [18]. PsA appears to be more frequent in men
than in women, particularly in its axial presentations [19].
Nevertheless, little is known of the differential clinical expres-
sion of PsA between males and females. The explanation
for these differences is not clear, and the participation of
multifactorial parameters cannot be discarded. In any case,
these clinical expression tendencies in men and women
with spondyloarthritis appear to persist in the more recently
published series [9].
We confirmed the greater peripheral involvement in
women with PsA (with more frequent polyarthritis), as
well as greater physical functional impairment as measured
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Table 3: Distribution of most significant markers in men and women with PsA.
(a)
Marker PsA females: 55 Female controls: 55
HLA-C∗06 31 (56.4%)OR: 6.6 (2.7–16.1), 𝑃
𝑐
= 0.0001
9 (16.4%)
HLA-C∗07 27 (49%)OR: 2.8 (1.3–6.3), 𝑃
𝑐
= 0.01
14 (25.5%)
TNF-308A 25 (45.5%)OR: 3.0 (1.3–6.9), 𝑃
𝑐
= 0.009
12 (22%)
MICA-A9 33 (60%)OR: 3.1 (1.4–6.7), 𝑃
𝑐
= 0.004
18 (32.7%)
HLA-B∗27 15 (27.3%)OR: 4.8 (1.5–15.5), 𝑃
𝑐
= 0.01
4 (7.3%)
(b)
Marker PsA males: 55 Male controls: 55
HLA-C∗06 31 (56.4%)OR: 5.8 (2.4–13.8), 𝑃
𝑐
= 0.0001
10 (18.2%)
MICA-A9 33 (60%)
OR: 4.0 (1.8–8.9), 𝑃
𝑐
= 0.001
15 (27.3%)
HLA-B∗27 20 (36.4%)OR: 7.3 (2.3–23.2), 𝑃
𝑐
= 0.0004
4 (7.3%)
Table 4: Distribution of most significant markers in men and women with PsA according to age at psoriasis onset (cutoff: 40 years).
(a) PsA females
Marker Age at onset <40: 40 Age at onset >40: 15 Female controls: 55
HLA-C∗06 26 (65%)OR: 9.5 (3.6–24.9), 𝑃
𝑐
= 0.0001
5 (33%) 9 (16.4%)
HLA-C∗07 20 (50%)OR: 2.9 (1.2–6.9), 𝑃
𝑐
= 0.02
7 (46.7%) 14 (25.5%)
TNF-308A 15 (37.5%) 10 (66.7%)OR: 9.0 (2.6–31.2), 𝑃
𝑐
= 0.0004
12 (22%)
HLA-DR17 4 (10%) 8 (53%)OR: 5.1 (1.5–17.5), 𝑃
𝑐
= 0.01
10 (18%)
MICA-A9 25 (62.5%)OR: 3.4 (1.5–8.0), 𝑃
𝑐
= 0.006
8 (53.3%) 18 (32.7%)
HLA-B∗27 12 (30%)OR: 5.5 (1.6–18.5), 𝑃
𝑐
= 0.005
3 (20%) 4 (7.3%)
(b) PsA males
Marker Age at onset <40: 45 Age at onset >40: 10 Male controls: 55
HLA-C∗06 26 (58%)OR: 6.2 (2.5–15.2), 𝑃
𝑐
= 0.0001
5 (50%)
OR: 4.5 (1.1–18.5), 𝑃
𝑐
= 0.04
10 (18.2%)
MICB-CA23 1 (2.2%) 5 (50%)OR: 17.3 (3.2–94.9), 𝑃
𝑐
= 0.001
3 (5.5%)
C1 4 4 (384) 12 (26.7%) 8 (80%)OR: 14.3 (2.7–76.6), 𝑃
𝑐
= 0.0007
12 (22%)
MICA-A9 27 (60%)OR: 4 (1.7–9.3), 𝑃
𝑐
= 0.001
6 (60%)
OR: 4.0 (1.0–16.2), 𝑃
𝑐
= 0.05
15 (27.3%)
HLA-B∗27 19 (42.2%)OR: 9.3 (2.9–30.2), 𝑃
𝑐
= 0.001
1 (10%) 4 (7.3%)
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with the HAQ. We do not know whether the same genetic
conditioning factors are operative in both males and females
with PsA, and the data found in the literature are very limited.
Apart from the mentioned relationship between HLA-B27
and the risk of psoriatic spondyloarthritis in males, the only
study of note corresponds to that published by Hu¨ffmeier et
al., who detected a greater frequency of the R620Wmutation
of the PTPN22 gene in males with PsA [20].
This study confirmed HLA-C∗06, B∗27, and MICA-A9
(∗002) as three of the most relevant PsA risk genes within
the MHC. All three were significantly overexpressed in men
and women with PsA. Our data corroborate the growing
importance of the PsA risk genes in the MHC. However,
these genetic profiles revealed differential characteristics
between men and women. Thus, women with psoriatic nail
disease were seen to express the C∗06 allele significantly
more often than men with the same disease. This finding
contrasts with the data published by Gudjonsson et al.,
who reported greater nail involvement in their HLA-C∗06
negative psoriatic patients [21]. These same authors found
C∗06 positive women to be younger at the time of onset
of psoriasis than C∗06 positive men—an observation not
recorded in our series [21]. In fact, among C∗06 positive men
with an age of over 40 years at onset of the disease, onset
proved significantly earlier than inC∗06 positivewomenwith
an age at onset of psoriasis of over 40 years. In turn, the HLA-
B∗27 positivity was a marker of early onset disease in both
sexes confirming recent observations [22].
Patient age at the onset of psoriasis has been a key
stratification element in studies of psoriasis. In this sense, it
has been known for decades that early psoriasis (manifesting
before 40 years of age) is associated with a family history
of disease, increased severity, and a stronger correlation
to HLA-C∗06 positivity, while late psoriasis (manifesting
after 40 years of age) appears to be milder, with no clear
genetic correlations [23, 24]. Our findings coincide with
these observations. However, in our series the impact of the
C∗06 allele upon disease risk was found to decrease more
clearly with age among females (only 33% of the women
with psoriasis onset above 40 years of age proved positive
for this allele) than in men (50% positivity for this allele in
individuals with late psoriasis onset). On the other hand,
allele 384 of the C4 1 1 microsatellite was associated with
late disease in men but not in women—though this allele
was in linkage disequilibrium (LD) with C∗06 (𝜆s: 0.6).
We found that certain markers that are overexpressed in
women, such asC∗07, TNF-308A andHLA-DR17 (DRB1∗03),
behave differently according to age at the onset of psoriasis.
Specifically, C∗07 was seen to be elevated in women with
early psoriasis, while the latter twomarkers were significantly
overexpressed only in women with late psoriasis. In women
there was a certain LD between TNF-308A, and DR17 (𝜆s:
0.3). In any case, it is interesting to note that C∗07, TNF-
308A, and DRB1∗03 form part of the extended haplotype
8.1, which also contains an allele recently linked to PsA risk
(HLA-B∗08); as a result, it is nowadays difficult to establish
which of these alleles are the true disease risk markers [25].
Thepresentwork has not been designed as a genetic study,
since the small number of patients involved clearly implies a
lack of the statistical power needed for such studies. Rather,
we aimed to determine whether there are genetic distinctions
between men and women that could help explain the little
known gender differences in the clinical expression of PsA.
Overall, our genetic findings are supported by recent data
confirming a good number of our observations referred to the
susceptibility role ofHLA-B∗27, C∗06, andC∗07 as risk alleles
in PsA [22, 25]. As a novelty, we have seen that the impact
of these genetic risk elements differs according to patient’s
gender and age at the onset of psoriasis.
5. Conclusions
In sum, men and women with PsA show differences in the
expression of the disease, and this is probably due in part to
a differential overexpression of certain MHC genes between
the two genders. We consider patient’s gender and age at the
onset of psoriasis to be key stratification factors that should
be considered in future studies of the associations between
MHC genes and the risk of PsA.
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